Acelrx pharmaceuticals inc (ACRX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Cash flows from operating activities:
Net loss

-15,925

-14,423

-12,731

-12,412

-13,674

-12,558

-12,458

-10,541

-11,592

-9,885

-13,013

-13,059

-15,551

-9,682

-11,402

-11,092

-10,981

-10,546

5,069

-8,896

-10,026

-13,818

671

-10,575

-9,631

17,769

-10,986

-17,447

-12,762

Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash royalty revenue related to royalty monetization

84

74

120

39

79

69

65

64

91

62

43

25

21

4

3

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest (income) expense on liability related to royalty monetization

-843

-962

-986

-996

1,607

1,617

2,913

2,995

2,816

2,786

2,768

2,609

2,558

2,461

2,401

2,324

2,196

2,146

282

0

0

-

-

-

-

-

-

-

-

Depreciation and amortization

487

515

419

406

328

140

142

144

149

356

440

468

480

507

516

517

512

482

505

509

488

397

151

156

162

154

151

147

141

Non-cash interest expense related to debt financing

271

241

237

135

99

124

145

163

181

205

589

380

91

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of premium/discount on investments, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-34

-27

-20

-29

-47

-68

-72

-68

-53

-52

-29

Non-cash interest expense related to debt financing

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

210

-

219

234

238

39

235

148

131

83

106

120

133

Restructuring costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

754

-

-

-

-

-

-

-

-

Stock-based compensation

1,146

1,278

1,326

1,346

1,107

1,232

1,808

1,048

1,080

1,054

1,018

1,078

1,144

1,071

1,078

1,145

1,185

1,190

1,171

1,111

1,538

1,372

1,199

894

975

1,044

876

802

757

Revaluation of put option and PIPE warrant liabilities

-

-

-

-

-

-

-

-

-

-

559

-321

197

-595

402

-199

-375

227

-215

12

-2,160

1,756

-7,077

-2,365

646

459

2,609

9,248

1,755

Other

-111

210

351

62

150

54

68

47

32

195

0

-2

5

0

0

-3

-14

-

-

-

-

-

-

-

-

-

-

-

-

Revaluation of put option and PIPE warrant liabilities

-

-

-

-

-

-

-

-

-

-

559

-321

197

-

-

-

-

-

-

-

-

-

-

-

-

-

2,609

9,248

1,755

Changes in operating assets and liabilities:
Accounts receivable

135

188

23

0

172

-138

-586

1

-761

190

-727

-638

-3,125

3,824

-2,176

979

-80

-14,090

17,376

0

0

-

-

-

-

-

-

-

-

Inventories

-88

411

991

441

1,549

-2

193

-3

-290

140

-486

-272

-302

770

56

418

444

466

0

0

0

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

-461

35

-202

-683

1,315

287

2

11

550

-399

-52

-47

323

-311

-170

-284

-210

848

-1,441

1,345

31

-363

203

-172

195

-120

-315

-780

83

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

45

Accounts payable

1,528

-862

284

-918

1,477

55

-66

-317

786

89

218

-650

652

-325

-1,503

-733

2,124

-222

270

-1,088

254

-438

71

613

-156

1,093

-50

-2,643

1,706

Accrued liabilities

-1,209

676

629

645

-809

686

1,073

428

-1,265

-1

-762

-487

-51

455

1,226

473

-1,515

1,614

-439

-728

-122

1,618

-873

1,141

-2,012

855

116

-454

-1,277

Operating lease liabilities

-181

-224

-164

-160

-153

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-79

17

-87

-192

43

-90

-90

-91

-91

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-90

-91

-90

-

207

270

603

-8

1,459

-486

-181

-226

176

-72

-95

-

-

-

-

Deferred rent

-

-

-

-

-

74

-26

-119

184

136

267

0

-43

-53

-52

-49

-48

-196

-38

-37

-13

-13

11

9

-29

-29

-29

-29

-26

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-8,238

-6,229

-

-5,510

-10,689

-10,749

-8,921

-5,592

-9,811

-10,132

-

-

-

-

Net cash used in operating activities

-14,364

-14,155

-11,466

-12,319

-13,240

-8,990

-6,301

-6,410

-7,374

-6,676

-6,784

-8,770

-7,535

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-9,672

Cash flows from investing activities:
Purchase of property and equipment

73

242

1,438

1,132

658

246

186

179

208

-90

534

1,425

536

1,839

1,573

118

190

334

228

378

516

749

2,797

816

1,143

1,921

1,213

101

52

Purchase of investments

12,757

18,144

53,768

24,285

3,871

17,714

0

11,849

995

7,565

0

0

0

-

-

-

-

2

1,721

3,075

2,468

2,546

10,005

3,520

1,359

2,305

7,682

9,657

8,365

Proceeds from maturities of investments

35,480

25,275

22,000

14,800

4,900

6,000

10,900

2,600

1,000

-

0

0

0

0

1,000

1,720

3,805

3,715

7,750

2,990

2,470

2,530

9,250

4,119

1,260

2,144

7,387

5,800

9,045

Net cash (used in) provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

609

3,615

-

5,801

-463

-514

-765

-3,552

-217

-1,242

-

-

-

-

Net cash provided by investing activities

22,650

6,889

-33,206

-10,617

371

-11,960

10,714

-9,428

-203

-7,475

-534

-1,425

-536

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

628

Cash flows from financing activities:
Payment of long-term debt

-

0

0

1,406

2,064

2,007

1,949

1,899

1,863

3,514

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

10,556

1,969

1,927

1,893

Net proceeds from issuance of common stock through equity plans

-

-

-

-

-

-

-

-

-

-

-

-

-

-

58

0

121

-

234

90

369

-517

1,657

169

560

276

1,248

149

84

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

121

-

58,909

-2,150

369

-517

1,657

10,169

560

-

-

-

-

Net proceeds from issuance of common stock in connection with equity financings

784

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from issuance of common stock through equity plans

218

1

317

155

270

914

163

0

141

57

190

11

93

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of employee tax obligations related to vesting of restricted stock units

86

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

916

1

1,550

14,695

-1,794

51,359

19,880

5,508

-1,722

-883

13,106

11

93

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,809

Net increase (decrease) in cash and cash equivalents

9,202

-7,265

-43,122

-8,241

-14,663

30,409

24,293

-10,330

-9,299

-

-

-

-

-12,152

-5,338

-7,629

-2,493

12,880

59,200

-13,302

-10,894

-10,203

-7,487

141

-10,814

27,606

38,876

-15,160

-10,853

Net decrease in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

-

-

-10,184

-7,978

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment in Accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

420

-

-

-

-